Study title:
High-Dose Tamoxifen and Sulindac as First-Line Treatment for Desmoid Tumors. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. Cancer 100(3)()(pp 612-620), 2004 Date of Publication: 01 Feb 2004 2004;(3):612-620. High-Dose Tamoxifen and Sulindac as First-Line Treatment for Desmoid Tumors. Hansmann A, Adolph C, Vogel T, Unger A, Moeslein G. Cancer 100(3)()(pp 612-620), 2004 Date of Publication: 01 Feb 2004 2004;(3):612-620.
Type of medicine: Medicines containing chemical active substances
|
Therapeutic area: Neoplasms [C04]
|
Brands: Please see report |
MAH holders: Please see report |
Assessment: |
Active substance: TAMOXIFEN |
ATC code: L02BA01 |
Document link:
|
Document date:
|
Study number: |
EudraCT number:
|
Scope of study: Clinical |
Population of study subjects:
|
Preterm newborn Infants
|
Newborn infants
(1 to 27 days)
|
Infants and toddlers
(28 days to 24 months)
|
Children
(2 to 11 years)
|
Adolescents
(12 to 18 years)
|
|
-
|
-
|
-
|
-
|
-
|